Targeting DED: Aiming Treatments at Optimal Results (Virtual CE Symposium)

June 20, 2024

To register for the symposium, please click Register (above) OR Take Course (on right).

Thursday, June 20, 2024
6:30 PM – 7:00 PM CT Registration and Dinner
7:00 PM – 9:00 PM CT CE Symposium and Virtual Broadcast

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Incorporate diagnostic strategies for DED into practice
  • Review the pathophysiologic factors of DED
  • Design evidence-based treatment plans for patients with DED
Course summary
Available credit: 
  • 2.00 COPE
  • 2.00 Participation
Course opens: 
Course expires: 
Event starts: 
06/20/2024 - 8:00pm EDT
Event ends: 
06/20/2024 - 10:00pm EDT


Kelly K. Nichols, OD, MPH, PhD, FAAO – Chair
Dean and Professor
University of Alabama at Birmingham School of Optometry
Birmingham, Alabama

Selina McGee, OD, FAAO 
Visionary Founder/Owner
BeSpoke Vision
Edmond, Oklahoma
Justin A. Schweitzer, OD, FAAO
Cataract, Cornea, Refractive, and Glaucoma Surgery Specialist
Vance Thompson Vision
Sioux Falls, South Dakota

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.


Kelly K. Nichols, OD, MPH, PhD, FAAO, is a consultant for ​​​AbbVie Inc,​​ ​​Alcon,​ ​​Alderya Therapeutics*,​ ​​Azura,​ ​​Bausch & Lomb​ Incorporated, ​​Bruder​ Healthcare, Cavalry, ​​Dompé US, Inc, ​​HanAll Biopharma, Harrow, Inc, ​​Novartis Pharmaceuticals Corporation/Takeda Pharmaceuticals USA, Inc*,​ ​​Osmotica Pharmaceuticals plc/RVL Pharmaceuticals, Inc*,​ ​​Nicox,​ ​​Novaliq​ GmbH, ​​Oyster Point​ Pharma, Inc, ​​Palatin​ Technologies, Inc, Thea​ ​​Phamra Inc, Tarsus​ Pharmaceuticals, Inc, Topcon Medical Systems, Inc, ​​TopiVert​ Ltd, ​​TearSolutions,​ ​​Trukera,​ ​​Verséa​ ​​Health, Inc, and Xequel​ Bio; is on the speakers bureau for ​​Bausch & Lomb​ Incorporated*;​ is a contracted researcher for ​​Sight Sciences,​ ​​TearScience,​ ​​Sylentis, ​​KOWA Pharmaceuticals America, Inc, and​ ​​Aramis​ Biosciences; and is a stockholder or has stock options in ​​Axim Biotechnologies Inc* and​ ​​Oyster Point​ ​Pharma, Inc*. 

Selina McGee, OD, FAAO, is a consultant for ​​​AbbVie Inc​, Aldeyra ​​Therapeutics, ​​Amgen Inc, Avellino,​​​ Bruder Healthcare, Cynosure, ​ Dompé US, Inc, ​Eyevance, Harrow, Inc, Horizon Therapeutics plc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Optovue, Incorporated, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, Topcon Medical Systems, Inc, Trukera, and Versant
Ventures​​; and is on the speakers bureau for ​​​AbbVie Inc​​, Bausch & Lomb Incorporated, Cynosure, ​ ​Dompé US, Inc, ​Lumenis, Optovue, Incorporated, Oyster Point Pharma, Inc​, and Tarsus Pharmaceuticals, Inc.

Justin A. Schweitzer, OD, FAAO, is a consultant for ​​​Aerie Pharmaceuticals, Inc, Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc,  Eyepoint Pharmaceuticals, Glaukos Corporation, Iveric Bio, Inc, Kala Pharmaceuticals, LKC Technologies, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Quidel Corporation, Reichert, Inc, RVL Pharmaceuticals, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Visus Therapeutics, and Zeiss​​; is on the speakers bureau for ​​​Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, LKC Technologies, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss; and ​​is on the advisory board of ​​​Aerie Pharmaceuticals, Inc, Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, Iveric Bio, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Visus Therapeutics, and Zeiss.​ 

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

COPE approval for 2.0 CE credits for optometrists pending.
COPE Course ID: TBD (synchronous in person); TBD (synchronous virtual)
COPE Course Category: Treatment and Management of Ocular Disease

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of  MedEdicus LLC or Bausch & Lomb Incorporated.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 319.4

Available Credit

  • 2.00 COPE
  • 2.00 Participation
Please login or register to take this course.

To register for this symposium, please make sure you are logged in to your account on the MedEdicus Learning Portal OR create an account above. It's quick and easy!

We look forward to having you participate on June 20!

If you do not receive an email confirmation, please check your spam folder or email